Charite Universitaetsmedizin Berlin KöR
Berlin, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying Rheumatoid Arthritis, a condition where the immune system mistakenly attacks the joints, causing pain and swelling. The study will explore the effects of a combined treatment using two medications: Abatacept and Daratumumab. Abatacept is a medication that helps to reduce the activity of the immune system, while Daratumumab is typically used to target specific cells in the immune system. Both medications are given as injections under the skin.
The purpose of this study is to assess the safety and effectiveness of the combined treatment in patients with a specific type of rheumatoid arthritis known as ACPA-positive. Participants will receive either the combined treatment or a placebo. The study will monitor participants over a period of time to observe any reactions to the injections and to see if there is an improvement in their condition. The study will also look at whether the treatment can change the levels of certain antibodies in the blood, which are often present in people with rheumatoid arthritis.
Throughout the study, participants will have regular check-ups to ensure their safety and to track any changes in their condition. The study aims to provide valuable information on whether this combined treatment can be a new option for managing rheumatoid arthritis. The trial is expected to continue until 2027, with recruitment starting in 2024.
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
438 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Berlin, Germany
Erlangen, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication used to treat rheumatoid arthritis. It works by interfering with the immune system's activity, helping to reduce inflammation and slow down the progression of the disease. In this trial, it is being used to see if it can help reset the immune system in patients with rheumatoid arthritis.
is a medication that targets specific cells in the immune system. It is commonly used in the treatment of certain types of blood cancers. In this trial, it is being tested to see if it can help reduce the activity of the immune system in patients with rheumatoid arthritis, potentially leading to an improvement in symptoms.
This medication is administered via intravenous infusion and is used to treat rheumatoid arthritis. It is currently well-established in medical practice and literature as a treatment for this condition. Abatacept works by interfering with the activation of T-cells, which are part of the immune system, thereby reducing inflammation and joint damage. It is classified as a selective co-stimulation modulator.
This medication is given through intravenous infusion and is primarily used in the treatment of multiple myeloma, but it is being studied for use in rheumatoid arthritis. It is an antibody that targets a specific protein on the surface of plasma cells, leading to their destruction. This action helps in reducing the immune response that contributes to rheumatoid arthritis. Daratumumab is classified as a monoclonal antibody.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.